| A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06035393) | Jiangsu HengRui Medicine Co., Ltd. | 2024-01-15 |
| Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects (NCT06198556) | Jiangsu HengRui Medicine Co., Ltd. | 2024-01-14 |
| SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen (NCT06123494) | Jiangsu HengRui Medicine Co., Ltd. | 2024-01-09 |
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval (NCT06196580) | Jiangsu HengRui Medicine Co., Ltd. | 2024-01-04 |
| A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures (NCT06216444) | Jiangsu HengRui Medicine Co., Ltd. | 2024-01-01 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects (NCT06922305) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-27 |
| Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (NCT06137469) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-26 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma (NCT06173999) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-22 |
| Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (NCT06139393) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-14 |
| Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects (NCT06168929) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-13 |
| A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy (NCT06169995) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-11 |
| A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis (NCT06144060) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-01 |
| A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy (NCT06126640) | Jiangsu HengRui Medicine Co., Ltd. | 2023-11-20 |
| A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites (NCT06086912) | Jiangsu HengRui Medicine Co., Ltd. | 2023-11-07 |
| Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects (NCT06093945) | Jiangsu HengRui Medicine Co., Ltd. | 2023-11-06 |
| A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (NCT06057610) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-16 |
| A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers (NCT06010680) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-07 |
| Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects (NCT06062680) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-01 |
| A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis (NCT06047483) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-01 |
| Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer (NCT06062355) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-01 |
| Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) (NCT06099990) | Jiangsu HengRui Medicine Co., Ltd. | 2023-10-01 |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer (NCT06006104) | Jiangsu HengRui Medicine Co., Ltd. | 2023-09-30 |
| A Trial of SP2086 With Hepatic Insufficiency (NCT06035406) | Jiangsu HengRui Medicine Co., Ltd. | 2023-09-01 |
| Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies (NCT05983146) | Jiangsu HengRui Medicine Co., Ltd. | 2023-09-01 |
| To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects (NCT05994378) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-29 |
| A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer (NCT05945901) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-14 |
| A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. (NCT06015048) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-11 |
| Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects (NCT05954169) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-07 |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT05942001) | Jiangsu HengRui Medicine Co., Ltd. | 2023-08-03 |
| A Study of SHR-A1811 in Subjects With Gynaecologic Oncology (NCT05896020) | Jiangsu HengRui Medicine Co., Ltd. | 2023-07-10 |
| An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. (NCT05884255) | Jiangsu HengRui Medicine Co., Ltd. | 2023-07-06 |
| A SHR-1210 BE Study on Healthy Subjects (NCT05799183) | Jiangsu HengRui Medicine Co., Ltd. | 2023-07-04 |
| SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (NCT05814354) | Jiangsu HengRui Medicine Co., Ltd. | 2023-06-30 |
| A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU (NCT05913336) | Jiangsu HengRui Medicine Co., Ltd. | 2023-06-27 |
| HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer (NCT05751850) | Jiangsu HengRui Medicine Co., Ltd. | 2023-06-13 |
| A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes (NCT05996380) | Jiangsu HengRui Medicine Co., Ltd. | 2023-06-09 |
| To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability (NCT05856058) | Jiangsu HengRui Medicine Co., Ltd. | 2023-05-29 |
| To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects (NCT05887895) | Jiangsu HengRui Medicine Co., Ltd. | 2023-05-23 |
| A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets (NCT05868057) | Jiangsu HengRui Medicine Co., Ltd. | 2023-05-23 |
| Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations (NCT06614153) | Jiangsu HengRui Medicine Co., Ltd. | 2023-05-16 |
| Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia (NCT05797623) | Jiangsu HengRui Medicine Co., Ltd. | 2023-04-26 |
| A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects (NCT05607693) | Jiangsu HengRui Medicine Co., Ltd. | 2023-04-26 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. (NCT05864014) | Jiangsu HengRui Medicine Co., Ltd. | 2023-04-25 |
| Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function (NCT07070375) | Jiangsu HengRui Medicine Co., Ltd. | 2023-04-19 |
| A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. (NCT05792410) | Jiangsu HengRui Medicine Co., Ltd. | 2023-04-01 |
| To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. (NCT05702073) | Jiangsu HengRui Medicine Co., Ltd. | 2023-03-31 |
| To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs (NCT05699408) | Jiangsu HengRui Medicine Co., Ltd. | 2023-03-31 |
| A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors (NCT05781048) | Jiangsu HengRui Medicine Co., Ltd. | 2023-03-23 |
| The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject (NCT05737576) | Jiangsu HengRui Medicine Co., Ltd. | 2023-03-20 |
| Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects (NCT05661591) | Jiangsu HengRui Medicine Co., Ltd. | 2023-02-28 |
| Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia (NCT05685420) | Jiangsu HengRui Medicine Co., Ltd. | 2023-01-23 |
| Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects (NCT05719961) | Jiangsu HengRui Medicine Co., Ltd. | 2023-01-05 |
| A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype (NCT05522439) | Jiangsu HengRui Medicine Co., Ltd. | 2022-12-22 |
| Study of SHR6390 in Renal Insufficiency and Healthy Subjects (NCT05515289) | Jiangsu HengRui Medicine Co., Ltd. | 2022-12-18 |
| Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects (NCT05592262) | Jiangsu HengRui Medicine Co., Ltd. | 2022-11-15 |
| A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects (NCT05560360) | Jiangsu HengRui Medicine Co., Ltd. | 2022-11-04 |
| A Trial of HR17031 Injection With Renal Insufficiency (NCT05292495) | Jiangsu HengRui Medicine Co., Ltd. | 2022-10-12 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. (NCT05476900) | Jiangsu HengRui Medicine Co., Ltd. | 2022-10-06 |
| Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT05533463) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-21 |
| A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants (NCT07189962) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-20 |
| A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (NCT05482568) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-15 |
| Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia (NCT05513976) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-15 |
| A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids (NCT05442827) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-10 |
| A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT05042375) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-08 |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (NCT05367687) | Jiangsu HengRui Medicine Co., Ltd. | 2022-09-01 |
| Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib (NCT05473468) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-26 |
| Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (NCT05473624) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-23 |
| A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy (NCT05549791) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-18 |
| A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis (NCT05324631) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-16 |
| A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients (NCT05214976) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-12 |
| A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery. (NCT05470075) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-11 |
| A Trial of SHR0410 Injection in Postsurgical Pain Management (NCT05394402) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-09 |
| A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (NCT05320692) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-09 |
| A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane (NCT05424835) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-04 |
| A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery. (NCT05470049) | Jiangsu HengRui Medicine Co., Ltd. | 2022-08-01 |
| A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer (NCT05425472) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-27 |
| A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers (NCT05392127) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-15 |
| A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (NCT05333835) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-08 |
| A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects (NCT05440006) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-03 |
| A Trial of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery (NCT05459220) | Jiangsu HengRui Medicine Co., Ltd. | 2022-07-01 |
| Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects (NCT05404724) | Jiangsu HengRui Medicine Co., Ltd. | 2022-06-25 |
| Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma (NCT05363800) | Jiangsu HengRui Medicine Co., Ltd. | 2022-06-17 |
| Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers (NCT05095337) | Jiangsu HengRui Medicine Co., Ltd. | 2022-06-07 |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS (NCT05277168) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-30 |
| Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers (NCT05370950) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-25 |
| A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (NCT05353361) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-23 |
| The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects (NCT05336071) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-12 |
| A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors (NCT05318833) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-12 |
| Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition (NCT05336279) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-11 |
| A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery (NCT05375305) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-11 |
| A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults (NCT05347498) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-30 |
| A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers (NCT05273775) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-29 |
| A Study of SHR-1802 in Patients With Advanced Solid Tumor (NCT05208177) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-22 |
| A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia (NCT05261646) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-15 |
| Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects (NCT05147727) | Jiangsu HengRui Medicine Co., Ltd. | 2022-03-14 |
| Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects (NCT05252546) | Jiangsu HengRui Medicine Co., Ltd. | 2022-03-08 |
| Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) (NCT05082233) | Jiangsu HengRui Medicine Co., Ltd. | 2022-03-06 |
| A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice (NCT05254366) | Jiangsu HengRui Medicine Co., Ltd. | 2022-01-30 |
| A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery. (NCT05318846) | Jiangsu HengRui Medicine Co., Ltd. | 2022-01-14 |
| A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC (NCT05106335) | Jiangsu HengRui Medicine Co., Ltd. | 2022-01-06 |